about
Asymmetric HIV-1 co-receptor use and replication in CD4(+) T lymphocytesUnsung Hero Robert C. GalloInhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 TatA general strategy to endow natural fusion-protein-derived peptides with potent antiviral activityPandemic vaccine preparedness--have we left something behind?Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypesPreclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.Nef-specific CD45RA+ CD8+ T cells secreting MIP-1beta but not IFN-gamma are associated with nonprogressive HIV-1 infection.Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms.TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements.Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation.Influenza A viruses grow in human pancreatic cells and cause pancreatitis and diabetes in an animal model.TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation.Restriction factors of retroviral replication: the example of Tripartite Motif (TRIM) protein 5 alpha and 22.The puzzling role of CXCR4 in human immunodeficiency virus infection.Lentiviral Effector Pathways of TRIM Proteins.Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein.HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter.Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort.Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection.Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharideA dimerizable cationic lipid with potential for gene delivery.Cytokine regulation of acute and chronic HIV infection in vitro: from cell lines to primary mononuclear cells.Cytokines in the acquired immunodeficiency syndrome and other infectious diseases.Rapid development of broadly influenza neutralizing antibodies through redundant mutations.Interleukin 10 increases CCR5 expression and HIV infection in human monocytesIdentification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease.HIV-1 isolation from infected peripheral blood mononuclear cells.Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection.Platelet derived growth factor induces ornithine decarboxylase activity in NIH 3T3 cells.Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression.The nef gene of human immunodeficiency virus type-1 (HIV1) is required for optimal virus replication in fully activated primary T lymphocytes.Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors.M1 polarization of human monocyte-derived macrophages restricts pre and postintegration steps of HIV-1 replication.Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity.Novel genetic association of TNF-α-238 and PDCD1-7209 polymorphisms with long-term non-progressive HIV-1 infection.CCR2-64I polymorphism, syncytium-inducing human immunodeficiency virus strains, and disease progression.Evaluation in rabbits of different anti-SHIV vaccine strategies based on DNA/fowlpox priming and virus-like particle boosting.Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages.
P50
Q21245460-7D9AA7A5-555B-4025-8122-A569BF6587ABQ22065525-D816671A-234B-4D96-A185-00FA4DE96B87Q22253931-8E68EF94-1301-43B3-8BE0-9C9959D88C0EQ28729918-996BE127-61AF-42C0-821D-4544BF3855D1Q30227832-031DB38C-5098-4736-894D-118D4F68E4A1Q30397298-86B5E43C-2A39-4EB6-99D0-A9D4CC40C04FQ30410546-532D4F69-E193-458A-8091-323A390E984CQ33399943-646EF249-BAB5-47F2-A031-31A2D5B68B78Q34016464-4ABD0305-1BA7-4F5C-8409-7920CF26987BQ34746588-28A7725C-7DE9-4558-B7E5-F403EC70B73BQ35076765-1097FDA2-53D8-46D7-B85C-E1CAE64DBC23Q35139327-DCB0CDD6-CFD2-48CC-BEC6-3D589BE68D3AQ36506875-A36A0A37-FEEE-4429-87E7-1A41E0BC96F4Q36760097-85AC9947-1570-404D-BE67-A81D54B702C0Q37639939-5D065289-CDB9-4758-9489-989FB3F9B480Q38079234-CF53192D-B9A6-4440-8B49-11C44953ACB3Q38194618-1DDDBF16-D712-4D32-BDE8-657148E05850Q38610308-D3ECA760-8C07-451F-8991-5348FA88CD69Q38810619-F90CD311-062C-419A-A94B-96778F005FEFQ39267280-EAEA7E18-2CC7-4AF0-91C1-CC3B125E0320Q39622285-164D4DD3-EA9F-4B08-8659-B9AE6C5F54FEQ39968970-2DF3766F-E7FE-4072-9AC4-47A330A0B1FFQ40002798-B398ACA8-AE67-4AAD-B484-34F6EF457C56Q40527497-A4F529F9-E68A-4867-8891-5BF5F0AA71E7Q40946275-A0ED8D6C-B6EC-4774-A11C-63E7B666AC39Q41710834-282B2723-2CED-4DD4-BF54-3B52994DBF41Q41779916-6186436A-8328-43E1-93B2-C98192576255Q42252136-B6B7FF39-396F-4DD4-A230-B9E0DF241CAAQ42259833-FE3C11B4-CA16-4051-9E5D-6D931C28566BQ42604793-8BBB3A92-D0A3-4C99-9BAD-635535D9B07EQ42816110-89F394AE-B03E-4C9E-A19E-03E7A10DE1BAQ43037178-F63F09A7-92A7-4BE7-8306-F5DC4FA192D3Q43458319-8078550A-F109-4790-A6E9-94EE0771060AQ43800064-5D5CC2FF-1138-420F-B1F7-FE5A62D960A2Q43837736-0D56825B-E2EF-4449-83FC-1A54F39CFD92Q44300776-632896AD-D393-40C7-A732-4D8D2C0E8731Q44541743-5C5BE5BA-511A-4B17-9262-1A1D5DF8432FQ44669580-4533F553-9C69-47C6-BF5E-4BCD44BB49E9Q44811986-3B7FCB02-7147-4891-B1BC-A288B8090B01Q45722952-26651FDA-4BEB-4C28-8D33-F11A1F2D9E22
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elisa Vicenzi
@ast
Elisa Vicenzi
@en
Elisa Vicenzi
@es
Elisa Vicenzi
@nl
Elisa Vicenzi
@sl
type
label
Elisa Vicenzi
@ast
Elisa Vicenzi
@en
Elisa Vicenzi
@es
Elisa Vicenzi
@nl
Elisa Vicenzi
@sl
prefLabel
Elisa Vicenzi
@ast
Elisa Vicenzi
@en
Elisa Vicenzi
@es
Elisa Vicenzi
@nl
Elisa Vicenzi
@sl
P106
P1153
7005411268
P21
P31
P496
0000-0003-0051-3968